Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 16/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150379 | 0.89 | CYP19A1 (0.70) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL12326973 | 0.85 | CYP19A1 (1.00) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL17082853 | 0.85 | CYP19A1 (0.71) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL16068156 | 0.85 | CYP19A1 (0.71) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL30774450 | 0.80 | BIRC5 (0.61) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL1131757 | 0.80 | BIRC5 (0.61) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL30557228 | 0.79 | CYP19A1 (0.58) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL12069252 | 0.79 | CYP19A1 (0.57) | CYP19A1MAPTCDC7CDK2 | |
| Hydrochloric Acid SCHEMBL30557205 | 0.78 | CYP19A1 (0.56) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL30775500 | 0.77 | MAPT (0.63) | CYP19A1MAPTCDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | CYP19A1 1821/4885MAPT 4008/4885CDC7 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.